LCTX Financials

Income Statement
MetricQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025
Revenue
1.7M
-73.9%
6.6M
+79.5%
3.7M
+33.1%
2.8M
+84.1%
1.5M
Cost of Revenue
0
0
0
0
0
Gross Profit
1.7M
-73.9%
6.6M
+79.5%
3.7M
+33.1%
2.8M
+84.1%
1.5M
Operating Expenses
9.3M
-29.2%
13.2M
+76.2%
7.5M
-66.9%
22.5M
+181.6%
8.0M
R&D
4.2M
-48.6%
8.2M
+151.8%
3.3M
+5.3%
3.1M
-0.3%
3.1M
SG&A
5.1M
+4.8%
4.9M
+15.8%
4.2M
-8.1%
4.6M
-6.1%
4.9M
Operating Income
-7593000
-16.0%
-6548000
-73.0%
-3786000
+80.9%
-19780000
-204.1%
-6505000
EBITDA
-7405000
-16.4%
-6362000
-76.3%
-3608000
+24.3%
-4769000
+24.8%
-6341000
Net Income
-4789000
-636.9%
892.0K
+103.0%
-29752000
+2.0%
-30364000
-632.9%
-4143000
EPS (Basic)
$-0.02
$0.00
+100.0%
$-0.13
+0.0%
$-0.13
-550.0%
$-0.02
EPS (Diluted)
$-0.03
$0.00
+100.0%
$-0.13
+0.0%
$-0.13
-550.0%
$-0.02
Shares (Diluted)
261.2M
+10.1%
237.2M
+3.6%
228.9M
+0.2%
228.4M
+1.0%
226.1M
Lineage Cell Therapeutics (LCTX) โ€” Financials